Literature DB >> 11895903

Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.

Chandrika J Piyathilake1, Andra R Frost, Uppender Manne, Heidi Weiss, Walter C Bell, Douglas C Heimburger, William E Grizzle.   

Abstract

PURPOSE: This study was conducted to evaluate the clinical significance of the localization of epidermal growth factor receptor (EGF-r), transforming growth factor (TGF)-alpha, and erbB-2 in the development, progression and prognosis of squamous cell cancers (SCCs) of the lung. EXPERIMENTAL
DESIGN: The localization of EGF-r, TGF-alpha, and erbB-2 was evaluated immunohistochemically in 60 archival specimens of SCC of the lung and in 60 lung specimens without cancer. To clarify the patterns of expression of EGF-r in these tumors, the patterns of expression of EGF-r in cells in culture were monitored after challenging normal human bronchial epithelial and SCC cell lines with either EGF or TGF-alpha at physiological concentrations. RESULTS AND
CONCLUSIONS: The expression of EGF-r, erbB-2, and TGF-alpha were significantly higher in SCC and associated precancerous lesions than in the normal bronchial epithelium and hyperplastic lesions of noncancer specimens. A statistically significant stepwise increase in expression from uninvolved bronchial epithelium to precancerous lesions to SCC was observed with EGF-r and TGF-alpha. The localization of EGF-r in the cytoplasm (P = 0.04), but not in the membrane (P = 0.20), of SCCs was significantly associated with poor overall survival of subjects. To demonstrate the biological relevance of cytoplasmic expression of EGF-r, we noted that there was a prompt reduction in the membrane expression and a concomitant increase in cytoplasmic expression of EGF-r after adding either EGF or TGF-alpha to the cell culture medium. Overall, the study identified an involvement of EGF-r and TGF-alpha in the development of SCCs. The prognostic importance of EGF-r expression in the cytoplasm of lung cancer probably is an indication of the prognostic importance of trafficking of the EGF-r receptor between the Golgi apparatus and cell membranes and of internalization of EGF-r after an interaction with one of the EGF-r ligands at the cellular membrane surface.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895903

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

2.  Cytoplasmic expression of c-erbB2 in non-small cell lung cancers.

Authors:  Chun-Mei Cheng; Koichi Tsuneyama; Kazuhiro Matsui; Hiroyuki Takahashi; Shin Ishizawa; Yasuo Takano
Journal:  Virchows Arch       Date:  2005-05-19       Impact factor: 4.064

3.  Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Authors:  Toni M Brand; Emily F Dunn; Mari Iida; Rebecca A Myers; Kellie T Kostopoulos; Chunrong Li; Chimera R Peet; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-09-01       Impact factor: 4.742

4.  Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

Authors:  Giuseppina Improta; Angela Zupa; Helen Fillmore; Jianghong Deng; Michele Aieta; Pellegrino Musto; Lance A Liotta; William Broaddus; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  J Proteome Res       Date:  2011-05-27       Impact factor: 4.466

5.  A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Authors:  Angela Zupa; Giuseppina Improta; Alessandra Silvestri; Elisa Pin; Jianghong Deng; Michele Aieta; Pellegrino Musto; Donato Nitti; Enzo Mammano; Lance Liotta; Claudio Belluco; Julia Wulfkuhle; Emanuel Petricoin
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

Review 6.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

7.  Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma.

Authors:  Peifeng Liu; Zonghai Li; Mingjie Zhu; Ying Sun; Yaogang Li; Hongzhi Wang; Yourong Duan
Journal:  J Mater Sci Mater Med       Date:  2010-02       Impact factor: 3.896

8.  Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.

Authors:  I Abdel Salam; H E Gaballa; N Abdel Wahab
Journal:  Med Oncol       Date:  2008-12-18       Impact factor: 3.064

9.  High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization.

Authors:  Ji Un Kang; Sun Hoe Koo; Kye Chul Kwon; Jong Woo Park; So Youn Shin; Jin Man Kim; Sung Su Jung
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

10.  Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Yi-Zih Kuo; Wang-Yi Kang; Guang-Yaw Liu; A-Mei Huang; Hong-Jeng Yu; Ming-Kuen Lai; Shu-Pin Huang; Wen-Jeng Wu; Shean-Jaw Chiou; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2009-09-12       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.